VTRS Q2 2023 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.9B-4.8% YoY

Gross Profit

$1.6B41.1% margin

Operating Income

$369M9.4% margin

Net Income

$264M6.7% margin

EPS (Diluted)

$0.22

QoQ Revenue Growth

+5.1%

Cash Flow

Operating Cash Flow

$525M

Free Cash Flow

$426M

Stock-Based Comp.

$39M

Balance Sheet

Total Assets

$48.7B

Total Liabilities

$27.9B

Stockholders' Equity

$20.8B

Cash & Equivalents

$629M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.9B	$4.1B	-4.8%
Gross Profit	$1.6B	$1.7B	-5.6%
Operating Income	$369M	$549M	-32.7%
Net Income	$264M	$314M	-15.9%

Revenue Segments

Brands

$2.4B63%

Generics

$1.3B34%

Complex GX and Biosimilars

$139M4%

Geographic Segments

Developed Markets Segment

$2.4B60%

Emerging Markets Segment

$648M17%

Greater China Segment

$532M14%

Japan, Australia and New Zealand Segment

$376M10%